Cartesian Therapeutics (RNAC) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to -$143.4 million.
- Cartesian Therapeutics' Enterprise Value rose 3458.7% to -$143.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$143.4 million, marking a year-over-year increase of 3458.7%. This contributed to the annual value of -$212.6 million for FY2024, which is 17643.64% down from last year.
- Latest data reveals that Cartesian Therapeutics reported Enterprise Value of -$143.4 million as of Q3 2025, which was up 3458.7% from -$160.3 million recorded in Q2 2025.
- In the past 5 years, Cartesian Therapeutics' Enterprise Value registered a high of -$76.9 million during Q4 2023, and its lowest value of -$219.2 million during Q3 2024.
- Moreover, its 5-year median value for Enterprise Value was -$138.7 million (2021), whereas its average is -$137.2 million.
- Per our database at Business Quant, Cartesian Therapeutics' Enterprise Value soared by 4564.2% in 2023 and then crashed by 17643.64% in 2024.
- Over the past 5 years, Cartesian Therapeutics' Enterprise Value (Quarter) stood at -$128.1 million in 2021, then fell by 5.11% to -$134.6 million in 2022, then soared by 42.86% to -$76.9 million in 2023, then tumbled by 176.44% to -$212.6 million in 2024, then surged by 32.56% to -$143.4 million in 2025.
- Its last three reported values are -$143.4 million in Q3 2025, -$160.3 million for Q2 2025, and -$180.4 million during Q1 2025.